260 related articles for article (PubMed ID: 11980998)
1. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Weingart J; Grossman SA; Carson KA; Fisher JD; Delaney SM; Rosenblum ML; Olivi A; Judy K; Tatter SB; Dolan ME
J Clin Oncol; 2007 Feb; 25(4):399-404. PubMed ID: 17264335
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
[TBL] [Abstract][Full Text] [Related]
5. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
J Clin Oncol; 2009 Mar; 27(8):1262-7. PubMed ID: 19204199
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Quinn JA; Desjardins A; Weingart J; Brem H; Dolan ME; Delaney SM; Vredenburgh J; Rich J; Friedman AH; Reardon DA; Sampson JH; Pegg AE; Moschel RC; Birch R; McLendon RE; Provenzale JM; Gururangan S; Dancey JE; Maxwell J; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
J Clin Oncol; 2005 Oct; 23(28):7178-87. PubMed ID: 16192602
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
[TBL] [Abstract][Full Text] [Related]
11. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C
Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; Chan DV; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD
Arch Dermatol; 2012 May; 148(5):613-20. PubMed ID: 22250189
[TBL] [Abstract][Full Text] [Related]
15. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
16. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
[TBL] [Abstract][Full Text] [Related]
19. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Batts ED; Maisel C; Kane D; Liu L; Fu P; O'Brien T; Remick S; Bahlis N; Gerson SL
Cancer Chemother Pharmacol; 2007 Aug; 60(3):415-21. PubMed ID: 17354015
[TBL] [Abstract][Full Text] [Related]
20. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
